Literature DB >> 26490863

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

Marija Usenovic1, Shahriar Niroomand2, Robert E Drolet2, Lihang Yao2, Renee C Gaspar2, Nathan G Hatcher2, Joel Schachter2, John J Renger2, Sophie Parmentier-Batteur1.   

Abstract

Neuronal inclusions of hyperphosphorylated and aggregated tau protein are a pathological hallmark of several neurodegenerative tauopathies, including Alzheimer's disease (AD). The hypothesis of tau transmission in AD has emerged from histopathological studies of the spatial and temporal progression of tau pathology in postmortem patient brains. Increasing evidence in cellular and animal models supports the phenomenon of intercellular spreading of tau. However, the molecular and cellular mechanisms of pathogenic tau transmission remain unknown. The studies described herein investigate tau pathology propagation using human neurons derived from induced pluripotent stem cells. Neurons were seeded with full-length human tau monomers and oligomers and chronic effects on neuronal viability and function were examined over time. Tau oligomer-treated neurons exhibited an increase in aggregated and phosphorylated pathological tau. These effects were associated with neurite retraction, loss of synapses, aberrant calcium homeostasis, and imbalanced neurotransmitter release. In contrast, tau monomer treatment did not produce any measureable changes. This work supports the hypothesis that tau oligomers are toxic species that can drive the spread of tau pathology and neurodegeneration. SIGNIFICANCE STATEMENT: Several independent studies have implicated tau protein as central to Alzheimer's disease progression and cell-to-cell pathology propagation. In this study, we investigated the ability of different tau species to propagate pathology in human neurons derived from induced pluripotent stem cells, which to date has not been shown. We demonstrated that tau oligomers, but not monomers, induce accumulation of pathological, hyperphosphorylated tau. This effect was accompanied with neurite degeneration, loss of synapses, aberrant calcium homeostasis, imbalanced neurotransmitter release, and ultimately with neuronal death. This study bridges various tau pathological phenotypes into a single and relevant induced pluripotent stem cell neuronal model of human disease that can be applied to the discovery of the mechanisms of tau-induced neurodegeneration.
Copyright © 2015 the authors 0270-6474/15/3514234-17$15.00/0.

Entities:  

Keywords:  Alzheimer's disease; hiPSC neurons; neurodegeneration; pathology propagation; tau oligomer seeds

Mesh:

Substances:

Year:  2015        PMID: 26490863      PMCID: PMC6605424          DOI: 10.1523/JNEUROSCI.1523-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

1.  Quantification of protein-protein interactions using fluorescence polarization.

Authors:  D M Jameson; S E Seifried
Journal:  Methods       Date:  1999-10       Impact factor: 3.608

2.  Quantification of beta-sheet amyloid fibril structures with thioflavin T.

Authors:  H LeVine
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

3.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 4.  Fluorescence polarization: past, present and future.

Authors:  David M Jameson; John C Croney
Journal:  Comb Chem High Throughput Screen       Date:  2003-05       Impact factor: 1.339

5.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 6.  Tau aggregation in the hippocampal formation: an ageing or a pathological process?

Authors:  André Delacourte; Nicolas Sergeant; Annick Wattez; Claude-Alain Maurage; Florence Lebert; Florence Pasquier; Jean-Philippe David
Journal:  Exp Gerontol       Date:  2002 Oct-Nov       Impact factor: 4.032

7.  Conformational change as one of the earliest alterations of tau in Alzheimer's disease.

Authors:  C L Weaver; M Espinoza; Y Kress; P Davies
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

8.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease.

Authors:  A Delacourte; N Sergeant; D Champain; A Wattez; C-A Maurage; F Lebert; F Pasquier; J-P David
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

9.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.

Authors:  P V Arriagada; J H Growdon; E T Hedley-Whyte; B T Hyman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 10.  The calpains in aging and aging-related diseases.

Authors:  Ralph A Nixon
Journal:  Ageing Res Rev       Date:  2003-10       Impact factor: 10.895

View more
  82 in total

1.  Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.

Authors:  Romany Abskharon; Paul M Seidler; Michael R Sawaya; Duilio Cascio; Tianxiao P Yang; Stephan Philipp; Christopher Kazu Williams; Kathy L Newell; Bernardino Ghetti; Michael A DeTure; Dennis W Dickson; Harry V Vinters; Philip L Felgner; Rie Nakajima; Charles G Glabe; David S Eisenberg
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

2.  Enhanced Tau Aggregation in the Presence of Amyloid β.

Authors:  Rachel E Bennett; Sarah L DeVos; Simon Dujardin; Bianca Corjuc; Rucha Gor; Jose Gonzalez; Allyson D Roe; Matthew P Frosch; Rose Pitstick; George A Carlson; Bradley T Hyman
Journal:  Am J Pathol       Date:  2017-05-10       Impact factor: 4.307

Review 3.  A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  Nat Rev Neurosci       Date:  2016-04       Impact factor: 34.870

Review 4.  Spreading of Pathology in Alzheimer's Disease.

Authors:  Zhong-Yue Lv; Chen-Chen Tan; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2017-06-16       Impact factor: 3.911

Review 5.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

6.  AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.

Authors:  A Borreca; V Latina; V Corsetti; S Middei; S Piccinin; F Della Valle; R Bussani; M Ammassari-Teule; R Nisticò; P Calissano; G Amadoro
Journal:  Mol Neurobiol       Date:  2018-03-05       Impact factor: 5.590

Review 7.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

8.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

9.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

10.  The Neurotoxic TAU45-230 Fragment Accumulates in Upper and Lower Motor Neurons in Amyotrophic Lateral Sclerosis Subjects.

Authors:  Claudia R Vintilescu; Sana Afreen; Ashlee E Rubino; Adriana Ferreira
Journal:  Mol Med       Date:  2016-08-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.